ARCHIVES

FDA Says Bristol’s UFT “Not Approvable” For Colorectal Cancer, Contrary To ODAC.

This article is from The Cancer Letter archive.

Vol. 27 No. 13 | March 30, 2001

Download PDF Visit The Full Archive

Related Articles

Cancer Policy: Board Plans Paper On Tobacco Control

June 13, 1997

Drug Shortage A Boon For Levoleucovorin; Price Is 60 Times Higher Than Leucovorin

January 16, 2009

In Brief: Richard Fisher Named Fox Chase President and CEO

August 2, 2013

Grand Jury Clears Eppley, Shubik

October 24, 1980

DeVita Distressed Over “Misinformation” Circulation On Organ Systems Program

April 8, 1983

“Triple-Negative” Should Be Split Into Subtypes, Say Researchers

February 22, 2013